eF-site ID 3iwm-D PDB Code 3iwm Chain D click to enlarge Title The octameric SARS-CoV main protease Classification HYDROLASE Compound 3C-like proteinase Source Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus) (3IWM) Sequence D:  SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT ILGSTILEDEFTPFDVVRQC Description Functional site 1) chain D residue 26 type sequence T description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 2) chain D residue 41 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 3) chain D residue 140 type sequence F description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 4) chain D residue 141 type sequence L description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 5) chain D residue 142 type sequence N description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 6) chain D residue 143 type sequence G description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 7) chain D residue 145 type sequence C description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 8) chain D residue 163 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 9) chain D residue 164 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 10) chain D residue 165 type sequence M description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 11) chain D residue 166 type sequence E description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 12) chain D residue 167 type sequence L description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 13) chain D residue 168 type sequence P description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 14) chain D residue 187 type sequence D description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 15) chain D residue 188 type sequence R description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 16) chain D residue 189 type sequence Q description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 17) chain D residue 190 type sequence T description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 18) chain D residue 191 type sequence A description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 19) chain D residue 192 type sequence Q description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 20) chain D residue 41 type catalytic sequence H description 830 source MCSA : MCSA4 21) chain D residue 143 type catalytic sequence G description 830 source MCSA : MCSA4 22) chain D residue 145 type catalytic sequence C description 830 source MCSA : MCSA4 23) chain D residue 41 type ACT_SITE sequence H description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 24) chain D residue 145 type ACT_SITE sequence C description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1

Display surface Download Links